Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 45 years old~* with a painful symptomatic endometriosis~* with symptoms evolve for more than 6 months~* diagnosis based on clinical and radiological criteria : pain in the examination and/or palpation of endometriosis lesion(s) and lesion(s) objectified by MRI performed and interpreted by a radiologist referent dating less than three months at the time of inclusion~* no history presenting therapeutic surgery for endometriosis~* Accepting medical management~* without hormonal treatment (oestroprogestative, progestative or Luteinizing Hormone-Releasing Hormone (LHRH) analog) since at least 15 days~* No family history of deep venous thromboembolic disorders~* No abnormalities of hemostasis known~* Not pregnant at inclusion visit~Exclusion Criteria:~* Patient with a strict indication for surgery (ureteral disease with renal impact, digestive disease with occlusion, infertility with desire for immediate pregnancy, ovarian cyst ≥ 4cm)~* reproductive upper tract infections~* with one or more varicose veins~* with one or more breast abnormalities (ACR 3 or more)~* with contraindication for one of two treatments~* with contraindication for RMI~* taking drug treatment that could alter the concentration of the study treatments

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Implant (Type: EXPERIMENTAL): Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
- Oral treatment (Type: ACTIVE_COMPARATOR): Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)

Based on this trial design, predict the completion outcome and termination type (if applicable).